Adavosertib (MK-1775)

For research use only. Not for use in humans.

目录号:S1525 别名: AZD1775

Adavosertib (MK-1775) Chemical Structure

CAS No. 955365-80-7

Adavosertib (MK-1775, AZD1775)是一种有效的,高选择性Wee1抑制剂,无细胞试验中IC50为5.2 nM;阻碍G2期DNA损伤检验点。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1960.96 现货
RMB 1376.38 现货
RMB 2226.67 现货
RMB 3835.28 现货
RMB 6297.29 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Adavosertib (MK-1775)发表文献123篇:

产品安全说明书

Wee1抑制剂选择性比较

生物活性

产品描述 Adavosertib (MK-1775, AZD1775)是一种有效的,高选择性Wee1抑制剂,无细胞试验中IC50为5.2 nM;阻碍G2期DNA损伤检验点。Phase 2。
特性 首个报道的 Wee1抑制剂。
靶点
Wee1 [1]
(Cell-free assay)
5.2 nM
体外研究

MK-1775以ATP竞争的方式抑制Wee1激酶。与作用于Wee1相比,MK-1775对Yes的效能低2-到3-倍,IC50为14 nM,对7种其他激酶的效能低10倍,1 μM浓度下抑制率>80%,比对人Myt 1选择性高100倍以上,并抑制周期蛋白依赖性激酶1 (CDC2) 在可选择位点(Thr14) 的磷酸化作用。通过阻断负荷突变型p53的WiDr细胞中Wee1活性,废止DNA损伤检控点,MK-1775治疗抑制Tyr15 (CDC2Y15)位点的CDC2基础磷酸化作用,EC50为49 nM,并剂量依赖性抑制gemcitabine-,carboplatin- 或cisplatin-诱导的CDC2磷酸化和细胞周期阻滞,EC50分别为82 nM和81 nM,180 nM 和163 nM,以及159 nM 和 160 nM。30-100 nM 的MK-1775单独治疗在WiDr 和 H1299细胞中没有显著的抗增殖作用,而300 nM的MK-1775足以抑制>80%的Wee1,表现出温和但显著的抗增殖作用,在WiDr和H1299细胞中抑制率分别为34.1%和28.4%。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
ASPC-1 NH6yfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy3NYRKSzVyPUGzMlIhyrFiMT6xJO69VQ>? NILLVIozPTR3OEm1OC=>
BxPC-3 NXXLRXl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfNTWM2OD1yLkigxtEhOC5yMzFOwG0> MkP5NlU1PTh7NUS=
CFPAC-1 NFfnZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTNwMzFCtUAxNjJizszN MWiyOVQ2QDl3NB?=
HPAC MoDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIWzVWJKSzVyPUCuOUDDuSByLkCxJO69VQ>? M2PtclI2PDV6OUW0
MIAPaCa-2 NIPVWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDJR|ZCUUN3ME2wMlUhyrFiMD6wOUDPxE1? MkTENlU1PTh7NUS=
PANC-1 MoruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2SwfGlEPTB;MUCuOkDDuSBzLkGg{txO MmDwNlU1PTh7NUS=
SK-N-BE (2) NWHyblRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvSTWM2OD1{LkVihKnDueLCiUCuN{DPxE1? MofvNlU{ODh7MU[=
SK-N-BE (2), PAN→MK Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHSTWM2OD1{Nj625qCKyrIkgJm5MlYh|ryP MUOyOVMxQDlzNh?=
SK-N-BE (2), MK→PAN M2XGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvFTYp{UUN3ME2yMlTjiIoEsfMAjVAvOyEQvF2= MkDuNlU{ODh7MU[=
SK-N-AS M{TReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjqTWM2OD1yLkWw5qCKyrIkgJmwMlAzKM7:TR?= MYCyOVMxQDlzNh?=
SK-N-DZ M{nncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwM{dihKnDueLCiUCuNFEh|ryP NFXMZoQzPTNyOEmxOi=>
SK-N-AS Mn;JRZBweHSxc3nzJGF{e2G7 NWPEbVJOPTByIH7N M{DSZlQ5KGh? Mnz4bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NYjheGR6OjV|MEi5NVY>
SK-N-DZ NU[zSFMySXCxcITvd4l{KEG|c3H5 MnLYOVAxKG6P NXjWcoY4PDhiaB?= MkHXbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MWWyOVMxQDlzNh?=
THP-1 M2fsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGxNlUwOjVyL{WwNEBvVQ>? MkPuOFghcA>? NILFe|hqdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MX2yOVA5PDZzNB?=
MV4-11 MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTKNVI2NzJ3MD:1NFAhdk1? Mn7QOFghcA>? MkXIbY5kemWjc3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> M1TMPFI2ODh2NkG0
U937 MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nqbVEzPS9{NUCvOVAxKG6P M1vrXlQ5KGh? MmfUbY5kemWjc3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NHq0NGQzPTB6NE[xOC=>
HL-60 M3jnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn4fHpoOTJ3L{K1NE82ODBibl2= NHrZcZE1QCCq MVzpcoNz\WG|ZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MVuyOVA5PDZzNB?=
OCI-AML3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3aTFN7OTJ3L{K1NE82ODBibl2= NXXSUJVbPDhiaB?= NF\vXVVqdmO{ZXHz[ZMh[2WubDDk[YF1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MXiyOVA5PDZzNB?=
MOLM-13 M{nX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L2WlEzPS9{NUCvOVAxKG6P M37XZlQ5KGh? MmPPbY5kemWjc3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NV7VZXlVOjVyOES2NVQ>
CMK M{jPVGNmdGxiVnnhZoltcXS7IFHzd4F6 MV6xNE0yODByMDDuUS=> M2TaeVczKGh? MXHy[YR2[2W|IHPlcIwhfmmjbHnibZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MYWyOFk3OjN|MR?=
CMY MULD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFfCOHoyOC1zMECwNEBvVQ>? MkTuO|IhcA>? NE\LfINz\WS3Y3XzJINmdGxidnnhcIljcXS7IHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ NFS2O5IzPDl4MkOzNS=>
Dayo M1T5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPnfmZKSzVyPUG1NEBvVQ>? Ml7PNlQ3PjF7MUC=
UW228 NEK2UIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjBTWM2OD1{M{Kgcm0> Mn7jNlQ3PjF7MUC=
IST-MES1 M{Hke2NmdGxiVnnhZoltcXS7IFHzd4F6 NVXofJRKOTVyL{K1NEBvVQ>? MnzFO|IhcA>? MlP5[Y5p[W6lZYOgeIhmKGOrc4DsZZRqdiCleYTveI95cWNiZX\m[YN1KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M1fNeVI1OzZ3N{iy
IST-MES2 NGDKd3RE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mmr0NVUxNzJ3MDDuUS=> M3uzRVczKGh? M3vpb4VvcGGwY3XzJJRp\SClaYPwcIF1cW5iY4n0c5RwgGmlIHXm[oVkfCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? Mm\ZNlQ{PjV5OEK=
REN MoHZR4VtdCCYaXHibYxqfHliQYPzZZk> NEn1[VUyPTBxMkWwJI5O NXPWSW1XPzJiaB?= NYLt[ppS\W6qYX7j[ZMhfGinIHPpd5Bt[XSrbjDjfZRwfG:6aXOg[YZn\WO2IHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ M4PQR|I1OzZ3N{iy
NCI-H2452 NIrEbppE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mn65NVUxNzJ3MDDuUS=> M1S5dVczKGh? MmDH[Y5p[W6lZYOgeIhmKGOrc4DsZZRqdiCleYTveI95cWNiZX\m[YN1KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M{TuclI1OzZ3N{iy
MSTO-211H NFHmWmNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M4HmTlE2OC9{NUCgcm0> M1rqZVczKGh? M3zKWoVvcGGwY3XzJJRp\SClaYPwcIF1cW5iY4n0c5RwgGmlIHXm[oVkfCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MUKyOFM3PTd6Mh?=
NCI-H2052 MVvD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHzHbpUyPTBxMkWwJI5O M2TGU|czKGh? Ml7G[Y5p[W6lZYOgeIhmKGOrc4DsZZRqdiCleYTveI95cWNiZX\m[YN1KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NXzFOmc1OjR|NkW3PFI>
WEE1 MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXmTWM2OD13LkKgcm0> NWnXfZhsOjN4OUm2OVU>
CDC2 MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzBSoplUUN3MP-8olExODBibl2= MYKyN|Y6QTZ3NR?=
CDK7 M1yzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|Ux97zgMUCwNEBvVQ>? NVLMepNzOjN4OUm2OVU>
MYT1 M{fVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3iybGlEPTB;NUOwJI5O MV:yN|Y6QTZ3NR?=
T98G  MlXQRZBweHSxc3nzJGF{e2G7 MlHJNVAxNzJ3MDDuUS=> MmO4OkBp MVjlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDj[YxtKGurbHzpcoc> Moi3NlE6QTJ5OUO=
A549 Mo\mRZBweHSxc3nzJGF{e2G7 MUOyNFAhdk1? NUi4foY1OSCq MmOydoFlcW:|ZX7zbZRqgmW|IF7TR2xEKGOnbHzzJIlvKGFicEWzMYRmeGWwZHXueEBu[W6wZYK= M4XMZlIyPzl7MEOz
H460 NWr1PGNkSXCxcITvd4l{KEG|c3H5 NI\0e3AzODBibl2= NWLvdG1zOSCq M{nERZJi\Gmxc3Xud4l1cXqnczDOV2NNSyClZXzsd{BqdiCjIIC1N{1l\XCnbnTlcpQhdWGwbnXy NFf3ZpozOTd7OUCzNy=>
H1299 MWHBdI9xfG:|aYOgRZN{[Xl? MX[yNFAhdk1? M2H6S|EhcA>? M3LhO5Ji\Gmxc3Xud4l1cXqnczDOV2NNSyClZXzsd{BqdiCjIIC1N{1l\XCnbnTlcpQhdWGwbnXy MnPINlE4QTlyM{O=
Calu-6  M3[yVWFxd3C2b4Ppd{BCe3OjeR?= NYXrUWs6OjByIH7N NWG5ZVJqOSCq NG\KNWJz[WSrb4PlcpNqfGm8ZYOgUnNEVENiY3XscJMhcW5iYTDwOVMu\GWyZX7k[Y51KG2jbn7ldi=> MXGyNVc6QTB|Mx?=
WiDr Mn[yT4lv[XOnIFHzd4F6ew>? M3\WbFExNTFyMECwJI5O MYK4JIg> NEj5bmhqdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhS0SFMjDheEBVgXJzNTD3bZRpKGGwIFXDOVDDqH[jbIXlJI9nKDh3IH7tc4wwVCCycnX0doVifGWmIIfpeIgh\2WvY3n0ZYJqdmV? M{fXc|E6QDh5NUS1

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Cdk1(Y15) / Cdk1; 

PubMed: 25609063     


The impact of a 24 hour pre-treatment of MK-1775 on p-Cdk1 was assessed by western blotting. Because of low basal phosphorylation, GBM22 was irradiated (RT) with 10 Gy.

p-KAP1(S824) / p-Chk2(T68) / p-Chk1(S345); 

PubMed: 25609063     


Western blot evaluation of GBM6 and GBM22 short-term explant cultures 24 hours after treatment with either MK-1775 or TMZ or the combination. 

PARP / CF-PARP / pH3(S10) / p-CDC25c(S216) / p-CDK2(Y15); 

PubMed: 25458954     


Pancreatic cancer cells were treated with vehicle control or 500 nM MK-1775 for 48 h. Whole cell lysates were subjected to Western blotting and probed with anti-PARP, -p-H3, -γH2AX, -p-CHK1, -CHK1, -p-CDC25C, -p-CDK1, - CDK1, -p-CDK2, -CDK2, or -β-actin antibody.

WEE1; 

PubMed: 27616351     


MIA PaCa2, PANC-1, Hs 766T, Capan-1 and PL11 cells were treated with MK-1775 (400 nM/L) and/or MMC (150 nM/L) for 24 hours. Whole cell lysates were prepared using RIPA and western blot was performed to assess the protein expression of WEE1 (90 kDa), pCDK1(y15) (34 kDa), CDK1 (34 kDa) and GAPDH (36 kDa) as loading control. 

25609063 25458954 27616351
Immunofluorescence
tubulin / p-HH3(S10); 

PubMed: 30755439     


FaDu and UNC7 cells were treated with adavosertib (500 nM), alisertib (250 nM), or adavosertib + alisertib for 24 hours and followed by immunofluorescent staining with anti-tubulin (Green) and anti-pHH3 (S10; Red). Nucleus was stained with DAPI. (A) Representative images of mitotic cells were captured by confocal microscopy. Scale bar: 10 µm.

γH2AX; 

PubMed: 25609063     


A) γH2AX foci formation in GBM6 and GBM22 were assessed 24 h after a single treatment of 300 nM MK-1775. 

Cleaved caspase-3 / pH3; 

PubMed: 27616351     


MIA PaCa2 cells were treated and dual stained with pH3 to observe mitotic entry; and cleaved caspase 3 (CL-CSP3) to observe caspase 3 activity.

30755439 25609063 27616351
Growth inhibition assay
Cell viability; 

PubMed: 25458954     


Pancreatic cancer cell lines were cultured in 96-well plates at 37℃ for 48 h in complete medium with variable concentrations of MK-1775 and viable cell numbers were determined using MTT reagent and a microplate reader. The data are presented as means ± standard errors from at least 3 independent experiments.

IC50; 

PubMed: 25084614     


AML cell lines were cultured for 72 h in complete medium with variable concentrations of MK-1775 (MK) and viable cell numbers were determined using MTT assays. IC50 values were calculated as drug concentration necessary to inhibit 50% growth compared to untreated control cells.

25458954 25084614
体内研究 MK-1775(~20 mg/kg)单独治疗对WiDr异种移植物表现出最小的抗肿瘤作用,在大鼠体内第3天时T/C为69%。在裸鼠HeLa-luc和TOV21G-shp53异种移植模型中,MK-1775单独的抗肿瘤效能是温和的。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

体外激酶试验:

使用重组人Wee1。激酶反应使用10 μM ATP,1.0 μCi of [γ-33P]ATP,和2.5 μg poly(Lys, Tyr)作为底物,在逐渐增加浓度的MK-1775存在下,在30°C环境中进行30分钟。整合到底物的放射性被捕获到MultiScreen-PH平板,在液体闪烁计数器上计数。
细胞实验:

[1]

- 合并
  • Cell lines: WiDr,NCI-H1299,TOV21G,和 HeLa细胞
  • Concentrations: 在DMSO中溶解,终浓度为~10 μM
  • Incubation Time: 24小时
  • Method: 细胞在gemcitabine存在或不存在下处理24小时,然后用MK-1775再处理24小时。细胞活性使用SpectraMax通过WST-8试剂盒测定。细胞内caspase-3/7活性使用Caspase-3/7 Glo试剂盒测定。
    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 负荷WiDr,HeLa-luc,或TOV21G-shp53肿瘤的免疫缺陷裸鼠(F344/NJcl-rnu)
  • Dosages: ~20 mg/kg/day
  • Administration: 口服
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 80 mg/mL (159.8 mM)
Water 0.0001 mg/mL (0.0 mM)
Ethanol ''10 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 500.6
化学式

C27H32N8O2

CAS号 955365-80-7
储存条件 粉状
溶于溶剂
别名 AZD1775

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03668340 Recruiting Drug: AZD1775 Uterine Cancer Dana-Farber Cancer Institute|AstraZeneca October 22 2018 Phase 2
NCT03028766 Active not recruiting Drug: AZD1775|Drug: Cisplatin|Radiation: Radiotherapy Hypopharynx Squamous Cell Carcinoma|Oral Cavity Squamous Cell Carcinoma|Larynx Cancer University of Birmingham|AstraZeneca|Cancer Research UK June 22 2017 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How to prepare MK1775 methylcellulose solution? and how to prepare methylcellulose itself? Once make the MK1775 methylcellulose solution, how should i keep it?

  • 回答:

    MK1775 in 0.5% methylcellulose is a suspension or emulsion, and it is ok to treat mice orally. It is recommended to dissolve methylcellulose in saline. It will take some time to dissolve methylcellulose, and you can vortex it for a while. The MK1775 methylcellulose solution can be stored at 4°C for a week.

Wee1 Signaling Pathway Map

相关Wee1产品

Tags: 购买Adavosertib (MK-1775) | Adavosertib (MK-1775)供应商 | 采购Adavosertib (MK-1775) | Adavosertib (MK-1775)价格 | Adavosertib (MK-1775)生产 | 订购Adavosertib (MK-1775) | Adavosertib (MK-1775)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID